Actavis buying Durata Therapeutics for $616.4

Published



CHICAGO (AP) — Specialty pharmaceutical company Actavis is buying Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio.

One of Durata’s key products is Dalvance for injection, an IV antibiotic for acute bacterial skin and skin structure infections. Dalvance was approved by the Food and Drug Administration in May.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.